PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Cyclosporine

Drugs in development · updated 30 October 2026

Cyclosporine: clinical trials and development status

Other names and codes: Ikervis, Verkazia, Vevizye, Restaysis

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 19 March 2015

As of 30 October 2026 Cyclosporine is in 46 active clinical trials (recruiting or ongoing, phases I–III) for 88 diseases. The most advanced phase is III.

46Active trials
IIIMost advanced phase
88Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Cyclosporine and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 88 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Acute myeloid leukemiaII–III11NCT02416388
Precursor lymphoblastic lymphoma/leukemiaII–III8NCT07366801
LeukemiaIII3NCT04547049
Membranous glomerulonephritisII–III2NCT07861204
Corneal ulcerIII1NCT06658002
Liver diseaseIII1NCT07739914
Myelodysplastic SyndromesII8NCT06013423
Aplastic anemiaII6NCT01624805
Chronic myelomonocytic leukemiaII5NCT00544115
Non-Hodgkin lymphomaII5NCT06013423
Acute biphenotypic leukaemiaII4NCT06013423
Hodgkin lymphomaII4NCT00544115
Myeloproliferative disordersII4NCT06013423
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveII3NCT06013423
Anaplastic large-cell lymphomaII2NCT00544115
Autoimmune diseaseII2NCT00977977
Burkitt lymphomaII2NCT00544115
Chronic lymphocytic leukemiaII2NCT00544115
Diffuse large B-cell lymphomaII2NCT00544115
Follicular lymphomaII2NCT00544115
Graft-versus-host diseaseII2NCT00544115
LymphomaII2NCT00544115
Lymphoma, B-Cell, Marginal ZoneII2NCT00544115
Mantle cell lymphomaII2NCT00544115
Multiple myelomaII2NCT00544115
MyelofibrosisII2NCT00544115
Refractory anemia with excess of blastsII2NCT00544115
Accelerated phase chronic myelogenous leukemiaII1NCT00544115
Acute monocytic leukemiaII1NCT03970096
Acute respiratory distress syndromeII1NCT04488081

Everything on Cyclosporine

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch